Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05014789 · ClinicalTrials.gov registry record · NA
Control-IQ Technology 2.0 Adult and Adolescent Feasibility Study
A NA study, sponsored by Tandem Diabetes Care.
- Completed
- Registry status
- NA
- Development phase
- 66
- Enrollment target
NCT05014789: Completed NA study, sponsored by Tandem Diabetes Care.
NCT05014789 is a NA study that has completed, run by Tandem Diabetes Care. The registered enrollment target is 66 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05014789, a NA study, has completed, sponsored by Tandem Diabetes Care.
- COMPLETED
- Registry status
- NA
- Development phase
- 66 participants
- Enrollment target
Study Summary
The purpose of this study is to obtain preliminary safety and performance data on planned improvements to Control-IQ technology.
Primary Outcome
CGM overall percent time less than 54 mg/dL, with different feature use of the pump each week.
Interventions
- DEVICE Control-IQ technology 2.0
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2021-08-19 |
| Est. Completion | 2021-12-20 |
| Phase | NA |
What the finished NCT05014789 record still lists
NCT05014789 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 66 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which Control-IQ technology 2.0 is the first listed.
NCT05014789 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05014789 about?
NCT05014789 is a clinical study titled "Control-IQ Technology 2.0 Adult and Adolescent Feasibility Study". The purpose of this study is to obtain preliminary safety and performance data on planned improvements to Control-IQ technology.
What is the current status of trial NCT05014789?
This trial is currently completed. It is a NA study. The enrollment target is 66 participants. The study started on 2021-08-19. Estimated completion is 2021-12-20.
What interventions are being tested in trial NCT05014789?
The interventions under investigation include: Control-IQ technology 2.0 (DEVICE).
Who is sponsoring clinical trial NCT05014789?
This trial is sponsored by Tandem Diabetes Care, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05014789's enrollment target sits among peer trials
66 1139th of 2000 higher than 857 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02584244 · 66 participants · Phase 1
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
- NCT03067051 · 66 participants · Phase 1
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
- NCT03754725 · 66 participants · Phase 1
Ferritin and Iron Burden in SAH sIRB
- NCT03875378 · 66 participants · Phase 2
Transdermal Estrogen in Women With Anorexia Nervosa
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI